|
Daily Medical Update
Lung cancer screening
Thursday, September 17, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
European radiology (2025) - Practice Guideline
Key Findings
- LDCT screening reduced the risk of lung cancer death by at least 21% in high-risk participants aged 50-75 years with at least 20 pack-years.
- Use of iterative reconstruction or deep-learning algorithms was recommended to reduce effective dose below 1 mSv.
- Watchful waiting for most subsolid nodules was recommended to reduce overtreatment, while solid nodules measuring 100-500 mm3 required 3- or 6-month follow-up.
📋 Practice Implication: Screening programs should pair proven mortality benefit with sub-1 mSv dose targets and risk-based nodule surveillance rather than reflexive intervention.
|
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP (2026) - Meta-Analysis
Key Findings
- Liquid biopsy-based multimodal models achieved 90.2% sensitivity and 83.6% specificity for pulmonary nodule classification.
- Performance exceeded CT-based evaluation, which had 81.5% sensitivity and 67.9% specificity.
- The multimodal models also outperformed risk prediction models, which had 68.7% sensitivity and 70.6% specificity.
📋 Practice Implication: For indeterminate nodules, liquid biopsy may serve as an adjunct to CT and clinical risk models to reduce unnecessary invasive work-up, while pathology remains decisive.
|
JAMA network open (2026) - Retrospective Cohort Study
Key Findings
- Cancer-related incidental findings occurred in 2,265 of 75,104 LDCT screening rounds (3.0%) and in 1,807 participants (6.8%).
- An extrapulmonary cancer was diagnosed within 1 year after 67 participants with a cancer-related incidental finding (3.0%).
- The adjusted marginal risk difference was 13.89 per 1,000 participants, increasing to 17.03 per 1,000 for urinary cancers.
📋 Practice Implication: Screening services should triage cancer-suggestive incidental findings for targeted evaluation, with particular attention to urinary tract signals, instead of pursuing undirected work-ups.
|
Cancer epidemiology (2026) - Comparative Study
Key Findings
- LDCT increased the odds of stage I disease for adenocarcinoma (adjusted odds ratio 2.48) and squamous cell carcinoma (adjusted odds ratio 1.71).
- Among diagnosed adenocarcinoma cases, LDCT was associated with lower lung cancer-specific mortality (adjusted hazard ratio 0.54), whereas no reduction was seen for squamous cell carcinoma (1.04).
- Squamous tumors had lower screening sensitivity, more frequent annual-round detection, and greater prediagnostic tumor-size increase than adenocarcinomas.
📋 Practice Implication: Patient counseling should explain that LDCT produces stage shift for both histologies, but the survival signal in this analysis was concentrated in adenocarcinoma and may be weaker for squamous disease.
|
Journal of the National Comprehensive Cancer Network : JNCCN (2026) - Practice Guideline
Key Findings
- The version 2.2026 update revised diagnostic workup and staging recommendations, improving standardization of small cell lung cancer care.
- Systemic therapy recommendations were updated to improve alignment with recent treatment changes.
- Radiation treatment recommendations were updated to improve alignment with recent treatment changes.
📋 Practice Implication: Clinicians managing suspected or confirmed small cell lung cancer should review the version 2.2026 diagnostic, systemic-therapy, and radiation updates before finalizing care pathways.
|
|
💡
Summary
The strongest evidence supports low-dose CT screening for high-risk adults, with careful dose control, nodule follow-up, and selective evaluation of incidental findings. Multimodal liquid-biopsy models improved pulmonary nodule discrimination, while National Lung Screening Trial data showed that stage shift and survival benefits differed by histology, favoring adenocarcinoma over squamous cell carcinoma.
|
|